DePuy Synthes signs exclusive distribution deal with CGBIO for bone graft
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
DePuy Synthes Enters Exclusive U.S., Canada and Australia Distribution Agreement for CGBIO’s NOVOSIS
May 26, 2026 8:00 AM EDTPartnership strengthens DePuy Synthes portfolio with a differentiated bone graft substitute containing growth factors to address unmet need across orthopaedic specialties
RAYNHAM, Mass.--(BUSINESS WIRE)-- DePuy Synthes, a global leader in orthopaedic technologies and solutions, today announced an exclusive distribution agreement1 with CGBIO, a biotechnology company specializing in regenerative medicine, for the development and commercialization of NOVOSIS, an advanced bone graft substitute containing growth factors, across its orthopaedic portfolio including spine, craniomaxillofacial (CMF), and trauma.
NOVOSIS is a novel growth-factor bone graft substitute designed to address unmet needs associated with existing solutions and... More
